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Abstract
Background: In Norway, women with negative or low-grade cervical biopsies (normal/CIN1) are followed up after six
months in order to decide on further follow-up or recall for screening at three-year intervals. A high specificity and positive
predictive value (PPV) of the triage test is important to avoid unnecessary diagnostic and therapeutic procedures whereas a
low risk of high-grade disease among triage negative women assures safety.
Materials and Methods: At the University Hospital of North Norway, cytology and the HPV mRNA test PreTect HPV-Proofer,
detecting E6/E7 mRNA from HPV types 16, 18, 31, 33 and 45, are used in post-colposcopy follow-up of women with negative
or low-grade biopsy. In this study, women with negative biopsy after high grade cytology (ASC-H/HSIL) and/or positive HPV
mRNA test in the period 2005–2009 were included (n=520). Histologically confirmed cervical intraepithelial neoplasia of
grade 2 or worse (CIN2+) was used as study endpoint.
Results: Of 520 women with negative or low-grade biopsy, 124 women (23.8%) had CIN2+ in follow-up biopsy. The
sensitivity and specificity of the HPV mRNA test were 89.1% (95% CI, 80.1–98.1) and 92.5% (95% CI, 88.2–96.7), respectively.
The ratios of sensitivity, specificity and PPV of HPV mRNA testing compared to repeat cytology for finding CIN2+ was 1.05
(95% CI: 0.92–1.21), 1.21 (95% CI: 1.12–1.32), and 1.49 (95% CI: 1.20–1.86), respectively. The PPV of mRNA was 77.3% (95% CI,
59.8–94.8) in women aged 40 or older.
Conclusion: Women with negative cervical biopsy require follow-up before resumption of routine screening. Post-
colposcopy HPV mRNA testing was as sensitive but more specific than post-colposcopy cytology. In addition, the HPV
mRNA test showed higher PPV. A positive mRNA test post-colposcopy could justify treatment in women above 40 years.
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Introduction
Cervical cancer is the third most common cancer affecting
women worldwide [1]. In Norway, about 300 women get cervical
cancer annually and 80–100 die from the disease [2]. Infection
with Human Papillomavirus (HPV) is a necessary cause of cervical
cancer [3]. In Norway, a cervical cancer screening program was
introduced in 1995, recommending all women between 25 and 69
years of age to have a cytological cell sample (Pap-smear) every
three years [4]. The rationale of cervical cancer cytological
screening is to identify and treat high-grade cervical intraepithelial
neoplasia (CIN) (precancerous lesions) in order to prevent its
progression to invasive cancer. Since the introduction of the
program, the coverage of women taking a Pap-smear has
increased and consequently, the rate of cervical cancer is reduced
[5]. Women with cytological diagnoses of either high grade
squamous intraepithelial lesion (HSIL) or atypical squamous cells,
cannot rule out a high grade lesion (ASC-H) are referred to
colposcopy and biopsy [4], as also recommended in European
guidelines [6,7]. The same is the case in women with atypical
squamous cells of undetermined significance (ASC-US) or low-
grade squamous intraepithelial lesion (LSIL) and positive HPV test
[8].
Unfortunately, colposcopy does not have optimal sensitivity for
CIN2+. The National Health Service Cervical Screening Pro-
gramme (NHSCSP) Guidelines for Colposcopy and Programme
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colposcopic accuracy of 65% [9]. Zuchna et al reported 66.2%
sensitivity of CIN2+ when up to three guided cervical biopsies
were taken regarded as a diagnostic test with the cone specimen as
reference standard [10]. Using digitized cervical images from 919
women referred for equivocal or minor cytologic abnormalities
into the ASCUS-LSIL Triage Study, Massad et al reported 39%
sensitivity for CIN2+ [11]. Hence, all women with negative
colposcopy and biopsies after abnormal cytology and/or HPV-
testing have to be followed. In Norway cytology and HPV testing
are used in post-colposcopy follow-up of women with negative
biopsy (normal or CIN1 histology) [8].
Several HPV tests for use in triage and follow-up are available
and different hospitals in Norway use different HPV tests. One of
these tests is the PreTect HPV-Proofer assay,detecting HPV E6/E7
mRNA from the five most prevalent subtypes causing cervical
cancer. The University Hospital of North Norway (UNN) has five
years of experience with the use of this test [8,12]. The argument for
choosing this test in triage of minor cervical lesions and follow-up
after negative biopsy was the need for a clinically specific test to find
the women truly needing referral to colposcopy, biopsy and
treatment. The HPV E6/E7 mRNA test has been shown to have
a higher clinical specificity and positive predictive value (PPV) than
HPV DNA tests [13–18] and thus qualifies better than HPV DNA
tests for this purpose. In post-colposcopy follow-up of women with
negative biopsy a triage test with high specificity is important to
reduce the number of unnecessary rebiopsies and avoid the adverse
effects of overdiagnosis and consequent overtreatment [19,20].
In three previous papers [8,12,21] we have reported targeted
prediagnostic management of women with minor cytological
abnormalities at screening. Now our hypothesis is that HPV E6/
E7 mRNA testing is more specific than follow-up cytology without
loss in sensitivity in postdiagnostic management of women who
have a negative biopsy.
Materials and Methods
The Regional Committee for Research Ethics (REK Sør-Øst C)
has approved the study. Written consent from the patients for their
information to be stored in the hospital database and used for
research was not needed because the data were obtained and
analyzed anonymously. The ethics committee specifically waived
the need for consent.
Study population
In the routine diagnostic practice at the University Hospital of
North Norway (UNN), the HPV E6/E7 mRNA test PreTect
HPV-Proofer (detecting E6/E7 mRNA from the HPV types 16,
18, 31, 33 and 45; (NorChip AS, Klokkarstua, Norway) is used in
the triage of women with a Pap-smear showing ASC-US or LSIL
and in post-colposcopy follow-up after negative biopsy. The
Department of Clinical Pathology receives cervical smears from
the population of Troms and Finnmark County. Approximately
23 000 cervical smears are analyzed each year. In 2005–2009,
smears from 63 740 women and cervical biopsies from 6 027
women aged 25–69 years were processed. A total of 1 484 women
Figure 1. Flow chart showing the two study populations.
doi:10.1371/journal.pone.0026022.g001
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with a positive HPV mRNA result.
Exclusion criteria
The following patients were excluded from the study: women
without a biopsy (n=199); women with CIN2+ on the first
biopsy who were referred to treatment (n=587); and women
with one or several abnormal Pap-smears and/or a positive
HPV-test at post-colposcopy follow-up but without re-biopsy
(n=178, Figure 1),
Considering the criteria above, 520 women with negative or
low-grade biopsy were included in the study. Among these, a
liquid based cytology (LBC) follow-up sample was taken for 192
women (36.9%), allowing for additional HPV mRNA testing
(HPV group). From the other 328 women (63.1%), a conventional
Pap-smear was received, not allowing for HPV analysis (cytology
only group, see Figure 1 and Table 1). The result of the follow-up
was compared to subsequent histology up to December 2010.
Cytology and HPV testing
In LBC, cells were extracted from the ThinPrepH 2000 (Cytyc
Corporation, Marlborough, MA, USA) for cytological examina-
tion. Of the remnant liquid with cervical cells, DNA/RNA was
isolated from 5 ml sample, eluted in 50 ml elution buffer and
analyzed with PreTect HPV-Proofer. The mRNA testing was
performed according to the manufacturer’s instructions (NorChip
AS) and in accordance with national guidelines for HPV testing
[8].
Diagnostic database
Cytological and histological diagnoses were obtained from the
diagnostic database (SymPathy) at the Department of Clinical
Pathology, UNN. Biopsies were evaluated by experienced
pathologists and histological results were reported using CIN
terminology [22]. In Norway, the threshold for treatment by
conization or LLETZ (large loop excision of the transformation
zone) is CIN2. Women with benign or CIN1 histology are advised
to be followed up with a new Pap-smear and HPV testing after 6–
12 months [8]. Biopsies with uncertain cellular changes are
analyzed with p16
INK4a immunostaining (CINtecH Histology,
MTM, Heidelberg, Germany) in order to detect occult CIN
lesions.
Study endpoint
Outcome assessment was based on the histological result of
biopsies, where CIN2+ was considered as the target disease and
CIN1 and CIN0 (no CIN) were considered as absence of disease.
Moreover, women with a complete negative follow-up (two
negative post-colposcopy Pap-smears or double negative liquid
based cytology (LBC) and HPV mRNA result) were assumed to be
free of disease. The clinical sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV) were
calculated in 262 tables for post-colposcopy cytology (with cut-off
ASC-US+ and ASC-H+, respectively), for the HPV-test alone and
HPV mRNA test in combination with cytology (with cut-off ASC-
US+ and ASC-H+).
Table 2. Outcome for the 328 women in the cytology only
group if triaged with post colposcopy cytology when cut-off
is ASC-US+.
Cytological
findings Outcome % 95% CI
CIN2+
1) ,CIN2
2) Total
3) Sensitivity 84.6 76.6, 92.6
ASC-US+ 66 59 125 Specificity 76.4 71.1, 81.7
NILM
4) 12 191 203 PPV 52.8 44.0, 61.6
Total 78 250 328 NPV 94.1 90.8, 97.4
1)Prevalence CIN2+ 23.8% (95% CI: 19.2–28.4).
2),CIN2 includes women with a histological diagnosis of CIN1 or CIN0 and
women referred back to screening because of two normal post colposcopy
smear.
3)Chi square=91.3, p,0.001.
4)NILM=Negative for intraepithelial lesion or malignancy.
doi:10.1371/journal.pone.0026022.t002
Table 3. Outcome for the 328 women in the cytology only
group if triaged with post-colposcopy cytology when cut-off
is ASC-H+.
Cytological
findings Outcome % 95% CI
CIN2+ ,CIN2 Total
1) Sensitivity 53.8 42.8, 64.9
ASC-H+ 42 9 51 Specificity 96.4 94.1, 98.7
,ASC-H 36 241 277 PPV 82.4 71.9, 92.8
Total 78 250 328 NPV 87.0 83.0, 91.0
1)Chi square=114.3, p,0.001.
doi:10.1371/journal.pone.0026022.t003
Table 1. Total number of women with negative cervical biopsy and later histologically confirmed CIN2+ by cytological result of
post-colposcopy cytology.
Follow-up cytology Number of women Number of women with CIN2+ PPV
1) (%) 95% CI
NIML
2) 304 17 5.6 3.0, 8.2
ASC-US 73 19 26.0 16.0, 36.1
LSIL 66 27 40.9 29.0, 52.8
ASC-H 44 33 75.0 62.2, 87.8
HSIL 33 28 84.4 72.6, 97.1
Total 520 124 23.8 20.1, 27.5
1)PPV=Positive predictive value for CIN2+.
2)NIML=Negative for intraepithelial lesion or malignancy.
doi:10.1371/journal.pone.0026022.t001
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Pearson’s Chi square was used to assess associations between
test results and final disease status. To assess differences in
accuracy, ratios of the sensitivity, specificity and PPV of mRNA
testing versus repeat cytology (and their 95% confidence intervals)
were computed. The McNemar Chi square test was used for
comparisons in sensitivity and specificity in the second follow-up
group where both the RNA test and repeat cytology were applied.
The Anova test was used to assess differences in average age of the
women in the cytology only group and in the HPV-test group. The
statistical computations were performed with the software R
version 2.9.0 (2009-04-17), http://www.r-project.org/. P-val-
ue,0.05 was considered statistically significant.
Results
In Table 1, outcomes by post-colposcopy cytology 6 months
after the negative biopsy are presented for all the 520 women
included. Furthermore, the PPVs for the different cytological
follow-up results are presented.
Of the 328 women in the post-colposcopy cytology only group
(Tables 2 and 3), 78 women (23.8%) had CIN2+. 207 women were
not referred to histology due to two normal post-colposcopy
cytology results considered as equivalent to ‘‘no disease’’, and 43
women had negative biopsy (normal or CIN1). Altogether, 250
women had a negative screening result in follow-up. The accuracy
for CIN2+ of triage with post-colposcopy cytology with cut-off
ASC-US+ is presented in Table 2. The estimates of sensitivity,
specificity, PPV and NPV were 84.6%, 76.4%, 52.8% and 94.1%,
respectively. With cut-off ASC-H+, the sensitivity was 53.8%, the
specificity 96.4%, the PPV 82.4% and the NPV 87.0% (Table 3).
Of the 192 women with post-colposcopy HPV mRNA test
(Tables 4, 5, and 6), 46 women (24.0%) had CIN2+. 120 women
were not referred to histology due to double negative cytology and
HPV result considered as equivalent to ‘‘no disease’’, and 26
women had negative biopsy (normal or CIN1). Altogether, 146
had negative screening result in follow-up. The accuracy
parameters for post-colposcopy follow-up with HPV mRNA are
shown in Table 4. The estimates of sensitivity, specificity, PPV and
NPV were 89.1%, 92.5%, 78.8%, and 96.4%, respectively. The
ratios of sensitivity, specificity and PPV of HPV mRNA testing (in
the 2
nd group) compared to repeat cytology (in the 1
st group) for
finding CIN2+ was 1.05 (95% CI: 0.92–1.21), 1.21 (95% CI: 1.12–
1.32), and 1.49 (95% CI: 1.20–1.86), respectively. These findings
were consistent with the intra-group comparison of mRNA testing
versus repeat cytology at ASC-US+ cutoff: equal sensitivity (p-
value for McNemar’s Chi square=1.00) and superior specificity of
mRNA testing (p-value for McNemar’s Chi2,0.001). The
detection rate of CIN2+ in follow-up of women with negative
biopsy by HPV mRNA positive/negative versus cytology abnor-
mal/normal is illustrated in Figure 2.
HPV mRNA test in combination with cytology with cut-off
ASC-US+ had a sensitivity of 97.8%, specificity of 63.0%, PPV of
45.5% and NPV of 98,9% (Table 5). The HPV mRNA test in
combination with cytology with cut-off ASC-H+ had sensitivity
93.5%, specificity 89.0%, PPV 72.9% and NPV of 97.7%
(Table 6).
Of the 520 women with negative biopsy, 124 women (23.8%)
had CIN2+, 72 women (13.8%) had CIN3+ and seven women
(1.3%) had cervical cancer in follow-up (Table 7). Five of the seven
women with cervical cancer were above 40 years of age (data not
shown).
Of the 192 women with post-colposcopy HPV mRNA test, one
woman (0.5%, 95% CI: 0.0–1.5) had cervical cancer. The woman
was HPV mRNA positive for HPV type 33. Of the 328 women in
the post-colposcopy cytology only group, six women (1.8%, 95%
CI: 0.4–3.3) had cervical cancer. Five of the six women had an
abnormal cytology. One woman had normal cytology (negative for
intraepithelial lesion or malignancy - NILM), but her cervical
cancer was detected by hysterectomy with indication uterine
leiomyoma (data not shown).
Discussion
Colposcopy and colposcopically-guided biopsies do not have
optimal sensitivity for detection of CIN2+. Of the 520 women with
negative biopsy, seven women actually had cervical cancer. For
Table 4. Outcome for the 192 women in the HPV group if
triaged by post-colposcopy HPV mRNA only.
HPV mRNA
result Outcome % 95% CI
CIN2+
1) ,CIN2
2) Total
3) Sensitivity 89.1 80.1, 98.1
Positive 41 11 52 Specificity 92.5 88.2, 96.7
Negative 5 135 140 PPV 78.8 67.7, 89.9
Total 46 146 192 NPV 96.4 93.3, 99.5
1)Prevalence CIN2+ 24.0% (95% CI: 17.9–30.0).
2),CIN2 includes women with a histological diagnosis of CIN1 or CIN0 and
women referred back to screening because of two normal post-colposcopy
smears or normal LBC and a negative HPV result.
3)Chi square=117.9, p,0.001.
doi:10.1371/journal.pone.0026022.t004
Table 5. Outcome for the 192 women in the HPV group if
triaged by post-colposcopy HPV mRNA combined with
cytology when cut-off is ASC-US+.
Combination
result Outcome % 95% CI
CIN2+ ,CIN2 Total
1) Sensitivity 97.8 93.6, 100.0
Positive 45 54 99 Specificity 63.0 55.2, 70.4
Negative 1 92 93 PPV 45.5 35.6, 55.3
Total 46 146 192 NPV 98.9 96.8, 100.0
1)Chi square=50.7, p,0.001.
doi:10.1371/journal.pone.0026022.t005
Table 6. Outcome for the 192 women in the HPV group if
triaged with post-colposcopy HPV mRNA combined with
cytology when cut-off is ASC-H+.
Combination
result Outcome % 95% CI
CIN2+ ,CIN2 Total
1) Sensitivity 93.5 86.3, 100.0
Positive 43 16 59 Specificity 89.0 84.0, 94.1
Negative 3 130 133 PPV 72.9 61.5, 84.2
Total 46 146 192 NPV 97.7 95.2, 100.0
1)Chi square=111.9, p,0.001.
doi:10.1371/journal.pone.0026022.t006
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been representative for the underlying disease. Alternatively, a
microlesion difficult to detect by colposcopy, colposcopy-directed
biopsies or by evaluation of histology may have been present.
Nevertheless, this emphasizes the need for additional methods in
order to increase the overall sensitivity of the screening algorithm
in the prevention of cervical cancer.
The current poor performance of colposcopic impression,
colposcopically-guided biopsies and histological diagnosis limits
the potential benefit of a very sensitive screening test [23]. In
Norway, for women with high grade cytology or HPV positive low
grade cytology, it is recommended two colposcopically-guided
biopsies and two random biopsies. If the colposcopy is normal,
biopsies from all four quadrants of the cervix is recommended, in
addition to an endocervical curette. Still, a considerable number of
women with a negative first biopsy have CIN2+ in the follow-up.
In our material 23.8% of the women with negative first biopsy
actually had CIN2+. Women with negative colposcopy and/or
negative biopsies require follow-up before resumption of routine
screening.
The main cause of invasive cervical cancer is the deregulated
and persistent production of HPV E6 and E7 oncoproteins [24].
Hence, HPV E6/E7 mRNA is a rational target for detecting HPV
infections leading to cellular transformation. PreTect HPV-
Proofer detects E6/E7 mRNA of the five main high-risk HPV
types 16, 18, 31, 33, and 45, which cause 86% of cervical cancers
in Europe [1,25]. Due to the higher clinical specificity and PPV of
this method compared to other HPV tests [13–18,26], this was the
method of choice at our hospital when HPV testing was
introduced in triage of women with minor cytological lesions
and in follow-up of women with negative biopsy.
When summarizing results from all women included in the
study (Table 1), 124 of 520 women (23.8%) had CIN2+ confirmed
by biopsy in follow-up. The PPV of post-colposcopy ASC-US or
LSIL in follow-up after negative biopsy were relatively low.
Previously, before HPV testing was included in clinical practice,
women with post-colposcopy ASC-US/LSIL were referred to
follow-up by a new cytology after 6–12 months. In current
practice, this is still the case for women with repeated ASC-US/
LSIL and a negative HPV mRNA result. Women with a positive
post-colposcopy HPV result however, are referred directly to a
Table 7. Diagnosis of the first cervical biopsy compared to
the most severe histological diagnosis.
Diagnosis of first
biopsy Most severe histological diagnosis
Normal CIN1 CIN2 CIN3 CxCa Total
Normal
1) 212 6 27 40 4 289
CIN1
2) - 178 25 25 3 231
Total 212 184 52 65 7 520
1)Of the women with normal biopsy 24.6% (95% CI: 19.6–29.5) had CIN2+ in
follow-up.
2)Of the women with CIN1 biopsy 22.9% (95% CI: 17.5–28.4) had CIN2+ in
follow-up.
doi:10.1371/journal.pone.0026022.t007
Figure 2. The detection rate of CIN2+ in follow-up of women with negative cervical biopsy by HPV mRNA positive/negative versus
cytology abnormal/normal.
doi:10.1371/journal.pone.0026022.g002
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therefore important in order to avoid unnecessary follow-up, both
with regard to follow-up costs to the health care system and with
regard to unnecessary psychological stress for the patients. In
addition, it is known that HPV tests identify lesions not found by
cytology and thereby contribute in increasing the overall clinical
sensitivity of the screening program [27–33].
It is also important to have in mind that in clinical practice, the
cytological diagnosis is commonly influenced by the HPV result.
We see a tendency that a preliminary diagnosis of for example
normal or ASC-US is upgraded when a positive HPV mRNA
result is acknowledged. As a result, the clinical sensitivity of
cytology as such will be over-estimated. In order to get two groups
for comparison, a study with two separate arms was conducted.
One arm with post-colposcopy repeat cytology only and one arm
with both repeat cytology and HPV test. National guidelines
recommend that a woman with negative biopsy should be followed
up with repeat cytology and an HPV test after 6–12 months. The
HPV-test however is not always performed due to use of
conventional Pap-smears instead of LBC, a method not allowing
for HPV testing. This made it possible to get a separate arm with
repeat cytology only. The HPV test result is objective and not
dependent on the cytological diagnosis. Women referred to
histology based on the cytological result alone (i.e., having a
negative HPV result) made it possible to calculate clinical
properties also including HPV negative results.
Until 2006, only conventional Pap-smears were used at our
hospital. When HPV-testing was introduced, liquid based cytology
was recommended, but still almost half of the samples for repeat
cytology are conventional Pap-smears. A limitation of the study is
the absence of formal randomization, which can result in
imbalanced groups. Still, one argument about comparability is
the similar age and similar prevalences of CIN2+. In the group
with cytology only, follow-up and in the HPV group, the average
age was 41.1 and 42.4 years, respectively (p=0.235). The median
age was 38 and 39 years, respectively. The prevalence of CIN2+
was similar in the two groups (23.8% and 24.0%, respectively).
Referral to biopsy in the HPV-category is based on both the
cytology and the HPV result and therefore does not represent the
true number of women referred to biopsy based on HPV testing
alone. For example, women with HSIL and ASC-H were always
referred to biopsy independent of the HPV result. Women with
ASC-US and LSIL were followed with new cytology after 12
months if the HPV mRNA test was negative.
With regard to follow-up cytology, statistical parameters were
calculated both at cut-off ASC-US+ and ASC-H+. The reason for
this is different follow-up in the two groups. Women with ASC-H+
are referred to colposcopy and biopsy. Women with ASC-US and
LSIL are followed up with cytology and HPV-testing. Post-
colposcopy cytology with cut-off ASC-US+ has a high sensitivity
(84.6%) for CIN2+, but only a moderate specificity (76.4%). In
contrast, repeat cytology with cut-off ASC-H+ has a low sensitivity
(53.8%), but a high specificity (96.4%). The combination of HPV
mRNA testing and cytology with cut-off ASC-H+ has both high
sensitivity (93.5%) and high specificity (89.0%).
The HPV mRNA data for women above and under 40 years of
age were analyzed separately. This was done both because older
age is associated with lower rates of regression of lesions, a higher
degree of recurrence after treatment of precancer and the risk of
obstetrical adverse effects is of less importance due to the lower
rate of planned children [19,20,34–37].
For the 97 women under 40 years of age with HPV mRNA test,
the estimates of sensitivity, specificity, PPV and NPV were 88.9%,
91.4%, 80.0% and 95.5%, respectively. For the 95 women above
40 years of age with HPV mRNA test, the estimates of sensitivity,
specificity, PPV and NPV were 89.5%, 93.4%, 77.3% and 97.3%,
respectively (Table 8).
In the present study, the HPV mRNA test shows a specificity of
92.5%. Previous data on HPV mRNA testing in the triage of ASC-
US and LSIL [8,12,21] show that the HPV mRNA test, due to a
high specificity and positive predictive value (PPV), is valuable in
the triage of women with minor cytological cervical lesions as it
gives important information in terms of further follow-up. In fact,
when the HPV result is positive, the data suggest direct treatment
for women above 40 years of age or for women with a concurrent
cytological HSIL diagnosis, contributing to better clinical safety for
these patients [8]. Benevolo et al reported 80% PPV for CIN2+ in
women with positive HPV mRNA and HSIL cytology [38].
Schiffman et al recommend direct treatment if the risk of CIN3+ is
high, for example 80–90% [23]. In the present study, the PPV for
CIN2+ for HPV mRNA positive in follow-up of women with
negative biopsy was 78.8%; the PPV was 80.0% for women under
Table 8. Outcome for the 97 women under 40 years and the 95 women above 40 years in the HPV group if triaged with post-
colposcopy HPV mRNA only.
HPV mRNA result Age,40 years Age.40 years
CIN2+ ,CIN2 Total
1) CIN2+ ,CIN2 Total
2)
Positive 24 6 30 17 5 22
Negative 3 64 67 2 71 73
Total 27 70 97 19 76 95
% 95% CI % 95% CI
Sensitivity 88.9 77.0, 100.0 89.5 75.7, 100.0
Specificity 91.4 84.9, 98.0 93.4 87.8, 99.0
PPV 80.0 65.7, 94.3 77.3 59.8, 94.8
NPV 95.5 90.6, 100.0 97.3 93.5, 100.0
Prevalence CIN2+ 27.8 18.9, 36.8 20.0 12.0, 28.0
1)Chi square=58.8, p,0.001.
2)Chi square=58.7, p,0.001.
doi:10.1371/journal.pone.0026022.t008
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Zuchna et al reported that colposcopy and biopsy had 66.2%
sensitivity of CIN2+ [10]. When a follow-up test for women with
negative biopsy has a high PPV for CIN2+, direct treatment is
more suitable than re-biopsies for women older than 40 years of
age if the triage test is positive. Given the impact of cervical
treatment (such as LLETZ or conization) on pregnancy outcomes
[19,20,35,37,39,40], cervical treatment is more critical for women
planning to have children. In addition, if a high-grade lesion is
found in a woman above 40 years of age, there is a higher chance
that the lesion has been present for a longer period of time, and at
higher risk of progression [34,41].
Women with negative biopsy require follow-up before resump-
tion of routine screening. In the present study, the HPV mRNA
test is as sensitive and significantly more specific than repeat
cytology at cut-off ASC-US+ in follow-up of women with negative
biopsy. Thus, the study findings provide evidence that supports
our hypothesis that HPV E6/E7 mRNA testing is more specific
than follow-up cytology without loss in sensitivity in postdiagnostic
management of women who have a negative biopsy. In addition,
the HPV mRNA test has a significantly higher PPV than cytology
alone. These data indicate that the HPV mRNA test is a better
follow-up test than cytology for women with negative biopsy.
When the follow-up test is HPV mRNA positive, our data suggest
direct treatment for women above 40 years of age contributing to a
better clinical safety for these patients. The use of HPV mRNA
test can reduce the time from a false negative biopsy to diagnosis
and treatment for CIN2+. Further studies are needed in order to
reveal whether post-colposcopy HPV mRNA testing and E6/E7
detection may replace cytology in follow-up of women with
negative biopsy.
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